Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is King International Investment Days Payable?
King International InvestmentHKSE:00928 -4.85% Days Payable is 64.57 as of Mar. 2026, which is 74% above its 10-year median of 37.11. The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, King International Investment ranks better than 50% on this metric.
The historical rank and industry rank for King International Investment's Days Payable or its related term are showing as below:
HKSE:00928'
s Days Payable Range Over the Past 10 Years
Min: 6.11 Med: 37.11 Max: 355.07
Current: 64.8
During the past 13 years, King International Investment's highest Days Payable was 355.07. The lowest was 6.11. And the median was 37.11.
HKSE:00928's Days Payable is ranked better than 50% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.795
vs HKSE:00928: 64.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00928 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, King International Investment's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
King International Investment Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's Days Payable distribution charts can be found below:
* The bar in red indicates where King International Investment's Days Payable falls into.
King International Investment Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
King International Investment (HKSE:00928) has a Days Payable of 64.57 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on King International Investment and its competitors. This is 74% above median its historical median of 37.11. Over the past decade, King International Investment's Days Payable has ranged from 6.11 to 355.07. According to the industry distribution chart, King International Investment ranks #95 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 50%.
Is King International Investment's Days Payable too high?
King International Investment's current Days Payable of 64.57 is 74% above median its 10-year median of 37.11. Over the past 10 years, this metric has ranged from a low of 6.11 to a high of 355.07. The Medical Diagnostics & Research industry median Days Payable is 64.80. King International Investment's value of 64.57 is 0.3% below this industry median. Based on the distribution chart, King International Investment ranks #95 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does King International Investment's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, King International Investment ranks #95 out of 190 companies for Days Payable. This puts King International Investment in the upper half of its industry. The industry median Days Payable is 64.80. King International Investment's value of 64.57 is 0.3% below this benchmark. Historically, King International Investment's own Days Payable has ranged from 6.11 to 355.07 over the past decade. While the company's 10-year median is 37.11 vs. the industry median of 64.80, King International Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.80, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. King International Investment's current Days Payable of 64.57 is 0.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on King International Investment and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. King International Investment's current Days Payable is 64.57, which is 74% above median its own 10-year median of 37.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is King International Investment stock overvalued right now?
Based on GuruFocus' analysis, King International Investment (HKSE:00928) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.10 — trading 145% above its estimated fair value. The current Days Payable is 64.57, which is 74% above median its 10-year median of 37.11 and 0.3% below the Medical Diagnostics & Research industry median of 64.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For King International Investment (HKSE:00928), the current Days Payable is 64.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
King International Investment Ltd is an investment holding company. Its operating segments include healthcare products and services, money lending, and liquor sales, with the majority of revenue generated from the liquor sales segment. The group provides genetic testing and develops domestic healthcare equipment services. Leveraging its strengths, the group integrates health data analysis software with healthcare equipment to offer new healthcare services and products. Geographically, it derives the majority of its revenue from the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00928 has been successfully added to your 
